GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Earnings per Share (Diluted)

SynAct Pharma AB (OSTO:SYNACT) Earnings per Share (Diluted) : kr-5.75 (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Earnings per Share (Diluted)?

SynAct Pharma AB's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was kr-0.70. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-5.75.

SynAct Pharma AB's EPS (Basic) for the three months ended in Mar. 2024 was kr-0.70. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-5.75.

SynAct Pharma AB's EPS without NRI for the three months ended in Mar. 2024 was kr-0.70. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was kr-5.75.

During the past 3 years, the average EPS without NRIGrowth Rate was -78.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -33.80% per year.

During the past 8 years, SynAct Pharma AB's highest 3-Year average EPS without NRI Growth Rate was 1.60% per year. The lowest was -78.90% per year. And the median was -23.70% per year.


SynAct Pharma AB Earnings per Share (Diluted) Historical Data

The historical data trend for SynAct Pharma AB's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Earnings per Share (Diluted) Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.62 -1.18 -2.68 -3.60 -6.64

SynAct Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -1.37 -1.00 -2.68 -0.70

Competitive Comparison of SynAct Pharma AB's Earnings per Share (Diluted)

For the Biotechnology subindustry, SynAct Pharma AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's PE Ratio falls into.



SynAct Pharma AB Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

SynAct Pharma AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-215.81-0)/32.524
=-6.64

SynAct Pharma AB's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-24.906-0)/35.571
=-0.70

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


SynAct Pharma AB  (OSTO:SYNACT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


SynAct Pharma AB Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines